• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Portola - Articles and news items

BMS, Pfizer and Portola team up to bring andexanet alfa to Japan

Industry news / 1 February 2016 / Victoria White

Andexanet alfa is designed to reverse the anticoagulant activity of Factor Xa inhibitors, including Eliquis (apixaban)…

Results of Phase 3 study of andexanet alfa presented at ISTH 2015

Industry news / 22 June 2015 / Victoria White

Full results from the second part of a Phase 3 trial evaluating the safety and efficacy of andexanet alfa as a reversal agent of Eliquis have been announced…

Portola, Bristol-Myers Squibb and Pfizer announce statistically significant results from the first part of the Phase 3 ANNEXA™-A studies of investigational Andexanet Alfa with Eliquis (apixaban)

Industry news / 18 November 2014 / Bristol-Myers Squibb Company

Bristol-Myers Squibb Company and Pfizer Inc. announced results from the first part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies…


Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +